MCID: PNC041
MIFTS: 52

Pancreatic Ductal Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Adenocarcinoma

MalaCards integrated aliases for Pancreatic Ductal Adenocarcinoma:

Name: Pancreatic Ductal Adenocarcinoma 38 12 15 73
Ductal Adenocarcinoma of the Pancreas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3498
NCIt 50 C9120
UMLS 73 C1335302

Summaries for Pancreatic Ductal Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that derives from pancreatic duct cells.

MalaCards based summary : Pancreatic Ductal Adenocarcinoma, also known as ductal adenocarcinoma of the pancreas, is related to cholangiocarcinoma and pancreatic cancer, and has symptoms including abdominal pain, icterus and pruritus. An important gene associated with Pancreatic Ductal Adenocarcinoma is MIR155 (MicroRNA 155
Relative expression levels of microRNA-155 in tissue and pancreatic juice samples were significantly higher in pancreatic ductal adenocarcinoma than those in chronic pancreatitis (P=0.014 and P=0.021, respectively). microRNA-155 in pancreatic juice has the potential of becoming biomarkers for diagnosing pancreatic ductal adenocarcinoma. miR-155 regulates T-cell activation and immune responses. Therefore, the main function of miR-155 might be the regulation of lymphocytes. Although the role of miR-155 in carcinogenesis or cancer progression has not been adequately understood, several articles have reported high expression levels of miR-155 in pancreatic ductal adenocarcinoma.). The drugs Gemcitabine and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and lymph node.

Related Diseases for Pancreatic Ductal Adenocarcinoma

Diseases related to Pancreatic Ductal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 31.0 AFAP1-AS1 H19 MALAT1 MIR21
2 pancreatic cancer 30.8 AFAP1-AS1 H19 HOTAIR HOTTIP LINC00673 MALAT1
3 melanoma 30.4 H19 HOTAIR HOTAIRM1 LINC00673 MALAT1 PVT1
4 gastric cancer 29.2 AFAP1-AS1 FEZF1-AS1 H19 HOTAIR HOTTIP LINC00673
5 adenocarcinoma 11.3
6 pancreatitis 11.3
7 esophagus squamous cell carcinoma 11.0 AFAP1-AS1 HOTAIR
8 polymyositis 11.0 MIR155 MIR21
9 triple-receptor negative breast cancer 11.0 HOTAIR MALAT1
10 pituitary adenoma 11.0 H19 HOTAIR MALAT1
11 ovarian epithelial cancer 11.0 H19 HOTAIR MALAT1
12 gastric cardia adenocarcinoma 10.9 H19 HOTAIR
13 malignant glioma 10.9 H19 HOTTIP MALAT1
14 lymphoma, hodgkin, classic 10.9 MIR155 MIR21 PVT1
15 prostate disease 10.9 H19 MALAT1
16 gallbladder cancer 10.9 AFAP1-AS1 H19 HOTAIR MALAT1
17 microvascular complications of diabetes 3 10.9 MALAT1 MIR21 PVT1
18 gastrointestinal system cancer 10.9 H19 HOTAIR MALAT1
19 astrocytoma 10.9 H19 HOTAIR MIR21 PVT1
20 squamous cell carcinoma, head and neck 10.9 H19 HOTAIR MIR155 MIR21
21 oral squamous cell carcinoma 10.8 H19 HOTAIR MALAT1 MIR155 MIR21
22 diffuse large b-cell lymphoma 10.8 HOTAIR MIR155 MIR21
23 small cell cancer of the lung 10.8 HOTAIR HOTTIP MALAT1 MIR21
24 kidney cancer 10.8 H19 HOTAIR MALAT1 MIR21 PVT1
25 lung cancer susceptibility 3 10.7 AFAP1-AS1 H19 HOTAIR MALAT1 MIR31HG
26 myeloma, multiple 10.7 H19 HOTAIR MALAT1 PVT1
27 esophagus adenocarcinoma 10.7 AFAP1-AS1 MIR21
28 tongue squamous cell carcinoma 10.7 AFAP1-AS1 HOTTIP LINC00673 MALAT1 MIR21
29 bladder urothelial carcinoma 10.7 HOTAIR MALAT1 PVT1
30 cervical cancer 10.7 H19 HOTAIR MALAT1 MIR21 PVT1
31 nasopharyngeal carcinoma 10.7 AFAP1-AS1 H19 HOTAIR MALAT1 PVT1
32 renal cell carcinoma, nonpapillary 10.6 H19 HOTAIR MALAT1 PVT1
33 clear cell renal cell carcinoma 10.6 MALAT1 MIR21 PVT1
34 thyroid cancer 10.6 AFAP1-AS1 H19 HOTAIR MALAT1 PVT1
35 bladder cancer 10.6 H19 HOTAIR MALAT1 MIR21 MIR31HG PVT1
36 glioma 10.5 H19 HOTAIR HOTTIP MALAT1 MIR21 PVT1
37 adamantinoma of long bones 10.5 AFAP1-AS1 H19 HOTAIR HOTTIP MALAT1 PVT1
38 leukemia, acute myeloid 10.5 HOTAIR HOTAIRM1 MALAT1 MIR155 MIR21 TUSC7
39 esophageal cancer 10.5 H19 HOTAIR HOTTIP MALAT1 MIR21 PVT1
40 glioblastoma 10.5 H19 HOTAIR HOTAIRM1 MALAT1 MIR21 TUSC7
41 osteogenic sarcoma 10.5 H19 HOTAIR HOTTIP MALAT1 PVT1 TUSC7
42 thyroid cancer, nonmedullary, 1 10.5 H19 HOTAIR HOTTIP MALAT1 MIR155 MIR21
43 ovarian cancer 10.5 AFAP1-AS1 H19 HOTAIR MALAT1 MIR155 MIR21
44 squamous cell carcinoma 10.4 H19 HOTAIR MALAT1 TUSC7
45 b-cell lymphomas 10.3 HOTAIR MALAT1 PVT1
46 hypoxia 10.3
47 autoimmune pancreatitis 10.3
48 duodenitis 10.1
49 hepatocellular carcinoma 10.1 AFAP1-AS1 H19 HOTAIR HOTTIP MALAT1 MIR155
50 diabetes mellitus 10.1

Graphical network of the top 20 diseases related to Pancreatic Ductal Adenocarcinoma:



Diseases related to Pancreatic Ductal Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Ductal Adenocarcinoma

UMLS symptoms related to Pancreatic Ductal Adenocarcinoma:


abdominal pain, icterus, pruritus

Drugs & Therapeutics for Pancreatic Ductal Adenocarcinoma

Drugs for Pancreatic Ductal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 95058-81-4 60750
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 33069-62-4 36314
3 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
4 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
5 Antimetabolites Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
6 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
7 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
8 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
9 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
10 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
11
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
12
Pancrelipase Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 53608-75-6
13
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
14
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
15 acivicin Phase 3,Phase 2
16 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 pancreatin Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
18 Adjuvants, Immunologic Phase 3
19 Viscosupplements Phase 3
20
Erlotinib Hydrochloride Phase 3,Phase 1,Phase 2 183319-69-9 176871
21 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
22
Cisplatin Approved Phase 1, Phase 2,Phase 2 15663-27-1 84093 441203 2767
23
Irinotecan Approved, Investigational Phase 2,Phase 1,Not Applicable 97682-44-5, 100286-90-6 60838
24
Oxaliplatin Approved, Investigational Phase 2,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
25
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
26
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
27
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
28
Propofol Approved, Investigational, Vet_approved Phase 2,Phase 1 2078-54-8 4943
29
nivolumab Approved Phase 2,Phase 1 946414-94-4
30
Coal tar Approved Phase 1, Phase 2 8007-45-2
31
Levoleucovorin Approved, Investigational Phase 2,Phase 1 68538-85-2
32
Pembrolizumab Approved Phase 1, Phase 2,Phase 2 1374853-91-4
33
Olaparib Approved Phase 2 763113-22-0 23725625
34
Bevacizumab Approved, Investigational Phase 1, Phase 2,Phase 2 216974-75-3
35
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
36
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
37
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
38
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
39
Metformin Approved Phase 1, Phase 2,Phase 2 657-24-9 14219 4091
40
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
41
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
42
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
43
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
44
leucovorin Approved, Nutraceutical Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
45
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
46
Vitamin C Approved, Nutraceutical Phase 1, Phase 2,Phase 2 50-81-7 5785 54670067
47
Camptothecin Experimental Phase 2,Phase 1 7689-03-4
48
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
49
Doxil Approved June 1999 Phase 2 31703
50
Cediranib Investigational Phase 2 288383-20-0 9933475

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Unknown status NCT02570529 Phase 4 Albis®;Placebo
2 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
3 A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenoca Recruiting NCT02715804 Phase 3 Placebo;Nab-paclitaxel;Gemcitabine
4 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
5 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Active, not recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
6 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer Not yet recruiting NCT03317886 Phase 3
7 Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Terminated NCT02101021 Phase 3 Momelotinib;Placebo to match momelotinib;Nab-paclitaxel;Gemcitabine
8 Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Unknown status NCT01893801 Phase 1, Phase 2 nab-paclitaxel;Cisplatin;gemcitabine
9 Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma Unknown status NCT01021800 Phase 2
10 Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Unknown status NCT02440958 Phase 2 modified FOLFIRINOX regimen
11 Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer Unknown status NCT02135822 Phase 2 nanoparticle albumin-bound paclitaxel;gemcitabine
12 Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
13 Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02289898 Phase 2 Demcizumab;Abraxane®;gemcitabine;Placebo
14 Scheduling Nab-paclitaxel With Gemcitabine Completed NCT03529175 Phase 2 Abraxane (nab-paclitaxel);Gemcitabine
15 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Completed NCT01580397 Phase 2 INNO-206
16 A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation Completed NCT02042378 Phase 2 Rucaparib
17 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Completed NCT00585078 Phase 2 Capecitabine;Oxaliplatin
18 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed NCT01658943 Phase 2 Akt Inhibitor MK2206;Fluorouracil;Oxaliplatin;Selumetinib
19 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Completed NCT01280058 Phase 2 Carboplatin;Paclitaxel
20 Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02426281 Phase 2 nab-paclitaxel;gemcitabine
21 Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02754726 Phase 2 Nivolumab;Albumin-bound paclitaxel;Paricalcitol;Cisplatin;Gemcitabine
22 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Recruiting NCT03193190 Phase 1, Phase 2 Nab-Paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Fluorouracil;Atezolizumab;Cobimetinib;PEGPH20;BL-8040
23 PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma Recruiting NCT02487277 Phase 2 PEGPH20;Gemcitabine;Nab-paclitaxel
24 A Phase II Study of Neoadjuvant FOLFIRINOX Recruiting NCT02178709 Phase 2 FOLFIRINOX
25 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
26 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) Recruiting NCT03415854 Phase 2 Paricalcitol (Zemplar)
27 Study of NAC of GA Therapy for Patients With BRPC Recruiting NCT02926183 Phase 2 Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
28 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Recruiting NCT02723331 Phase 2 Nab-paclitaxel and gemcitabine for R-PDAC Patients;Nab-paclitaxel and gemcitabine for BR-PDAC Patients
29 A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy Recruiting NCT03331640 Phase 2 OFF;FOLFIRI Protocol
30 A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Recruiting NCT01676259 Phase 2 siG12D-LODER;Gemcitabine+nab-Paclitaxel
31 Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Recruiting NCT02125136 Phase 2 Gem/nab-Pac;FOLFIFINOX
32 Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. Recruiting NCT03525392 Phase 1, Phase 2 177Lu-3BP-227 (also called 177Lu-IPN01087)
33 Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Recruiting NCT02047513 Phase 2 perioperative nab-paclitaxel/gemcitabine;adjuvant nab-paclitaxel/gemcitabine
34 A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Recruiting NCT02880371 Phase 1, Phase 2 ARRY-382;Pembrolizumab
35 Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer Recruiting NCT02806687 Phase 2 Gene Therapy product CYL-02;Gemcitabine
36 Efficacy and Safety of PARPi to Treat Pancreatic Cancer Recruiting NCT02511223 Phase 2 OLAPARIB
37 Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma Recruiting NCT02743975 Phase 1, Phase 2 Bevacizumab-800CW
38 A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors Recruiting NCT03267316 Phase 1, Phase 2
39 Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) Recruiting NCT03410030 Phase 1, Phase 2 Ascorbic Acid;Paclitaxel protein-bound;Cisplatin;Gemcitabine
40 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Recruiting NCT02498613 Phase 2 Cediranib Maleate;Olaparib
41 A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) Recruiting NCT03085914 Phase 1, Phase 2 Epacadostat;Pembrolizumab;Oxaliplatin;Leucovorin;5-Fluorouracil;Gemcitabine;nab-Paclitaxel;Carboplatin;Paclitaxel;Pemetrexed;Cyclophosphamide;Carboplatin;Cisplatin
42 Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy Recruiting NCT03404960 Phase 1, Phase 2 Niraparib + Nivolumab;Niraparib + Ipilimumab
43 Olaparib for BRCAness Phenotype in Pancreatic Cancer Recruiting NCT02677038 Phase 2 Olaparib
44 A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT02981342 Phase 2 Abemaciclib;LY3023414;Gemcitabine;Capecitabine
45 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Active, not recruiting NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
46 Study of Tremelimumab in Patients With Advanced Solid Tumors Active, not recruiting NCT02527434 Phase 2
47 Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer Active, not recruiting NCT02124317 Phase 2 nanoparticle albumin-bound paclitaxel;S-1
48 Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla Active, not recruiting NCT02626520 Phase 2 Gemcitabine and nanoparticle albumin bound paclitaxel;5-fluorouracil and irinotecan
49 Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Active, not recruiting NCT02562898 Phase 1, Phase 2 Ibrutinib;Paclitaxel;Gemcitabine
50 A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer Active, not recruiting NCT02048384 Phase 1, Phase 2 metformin alone (Arm A);metformin (Arm B);rapamycin (Arm B)

Search NIH Clinical Center for Pancreatic Ductal Adenocarcinoma

Genetic Tests for Pancreatic Ductal Adenocarcinoma

Anatomical Context for Pancreatic Ductal Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Ductal Adenocarcinoma:

41
Pancreas, Lymph Node, T Cells, Liver, Neutrophil, Testes, Placenta
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Ductal Adenocarcinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Ducts Affected by disease

Publications for Pancreatic Ductal Adenocarcinoma

Articles related to Pancreatic Ductal Adenocarcinoma:

(show top 50) (show all 1032)
# Title Authors Year
1
Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. ( 29973215 )
2018
2
Targeting dendritic cells in pancreatic ductal adenocarcinoma. ( 29946224 )
2018
3
Ro60/SSA levels are increased and promote the progression of pancreatic ductal adenocarcinoma. ( 29274781 )
2018
4
Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species. ( 29393401 )
2018
5
Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. ( 29948075 )
2018
6
Imaging features of pancreatic metastases: A comparison with pancreatic ductal adenocarcinoma. ( 29448123 )
2018
7
Pattern, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma: how do they matter? ( 29963395 )
2018
8
Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. ( 29404819 )
2018
9
The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma. ( 29416345 )
2018
10
High expression of RACK1 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. ( 29434907 )
2018
11
Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma. ( 29413686 )
2018
12
Silver nanoparticles of different sizes induce a mixed type of programmed cell death in human pancreatic ductal adenocarcinoma. ( 29435134 )
2018
13
MRI evaluation of pancreatic ductal adenocarcinoma: diagnosis, mimics, and staging. ( 29967986 )
2018
14
LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma. ( 29960845 )
2018
15
SALL4 suppresses reactive oxygen species in pancreatic ductal adenocarcinoma phenotype via FoxM1/Prx III axis. ( 29958885 )
2018
16
Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma. ( 29397657 )
2018
17
CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis. ( 29931561 )
2018
18
Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma. ( 29975352 )
2018
19
Reply to: Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. ( 29938375 )
2018
20
A phase I trial of the I^-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. ( 29438372 )
2018
21
MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma. ( 29940895 )
2018
22
A novel prognostic biomarker for pancreatic ductal adenocarcinoma: hsa_circ_0001649. ( 29969694 )
2018
23
MRI of pancreatic ductal adenocarcinoma: texture analysis of T2-weighted images for predicting long-term outcome. ( 29980829 )
2018
24
Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma. ( 29542402 )
2018
25
Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth. ( 29248719 )
2018
26
Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. ( 29435115 )
2018
27
Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma. ( 29962812 )
2018
28
Intravoxel incoherent motion magnetic resonance imaging for differentiating metastatic and non-metastatic lymph nodes in pancreatic ductal adenocarcinoma. ( 29404768 )
2018
29
"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017": Will this pull us up out of the quagmire of confusing definitions and criteria? ( 29389525 )
2018
30
LncRNA BC032020 suppresses the survival of human pancreatic ductal adenocarcinoma cells by targeting ZNF451. ( 29532883 )
2018
31
Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. ( 29951629 )
2018
32
Overexpression of I+3, I^3 and I^2 chains of laminin-332 is associated with poor prognosis in pancreatic ductal adenocarcinoma. ( 29928402 )
2018
33
KrA1ppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice. ( 29248441 )
2018
34
Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. ( 29948425 )
2018
35
Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma. ( 29440233 )
2018
36
High expression of microRNA-4295 contributes to cell proliferation and invasion of pancreatic ductal adenocarcinoma by the down-regulation of Glypican-5. ( 29407175 )
2018
37
Adverse Oncologic Impact of New-Onset Diabetes Mellitus on Recurrence in Resected Pancreatic Ductal Adenocarcinoma: A Comparison With Long-standing and Non-Diabetes Mellitus Patients. ( 29975349 )
2018
38
Upregulated long non-coding RNA SPRY4-IT1 predicts dismal prognosis for pancreatic ductal adenocarcinoma and regulates cell proliferation and apoptosis. ( 29551494 )
2018
39
MiR-7-5p functions as a tumor suppressor by targeting SOX18 in pancreatic ductal adenocarcinoma. ( 29408481 )
2018
40
Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection. ( 29976637 )
2018
41
Systemic Depletion of Nerve Growth Factor Inhibits Disease Progression in a Genetically Engineered Model of Pancreatic Ductal Adenocarcinoma. ( 29975347 )
2018
42
Interleukin 35 Expression Correlates With Microvessel Density inA Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice. ( 28989066 )
2018
43
CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma. ( 29298720 )
2018
44
S-1 induced discoid lupus erythematosus-like lesions and long-term complete response for para-aortic lymph node recurrence of pancreatic ductal adenocarcinoma: a case report. ( 29882080 )
2018
45
Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma. ( 29392613 )
2018
46
High expression of diffuse panbronchiolitis critical region 1 gene promotes cell proliferation, migration and invasion in pancreatic ductal adenocarcinoma. ( 29242154 )
2018
47
The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: What should be the surgeon's choice? ( 29387699 )
2017
48
Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. ( 28108627 )
2017
49
MRGBP as a potential biomarker for the malignancy of pancreatic ductal adenocarcinoma. ( 28969065 )
2017
50
Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells. ( 28775207 )
2017

Variations for Pancreatic Ductal Adenocarcinoma

Copy number variations for Pancreatic Ductal Adenocarcinoma from CNVD:

7 (show top 50) (show all 315)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14616 1 109662726 110421733 Loss Pancreatic ductal adenocarcinoma
2 14979 1 111694621 112653686 Loss Pancreatic ductal adenocarcinoma
3 15141 1 11296895 11700048 Loss Pancreatic ductal adenocarcinoma
4 15254 1 113902673 114772618 Loss Pancreatic ductal adenocarcinoma
5 21071 1 156591077 157602759 Gain Pancreatic ductal adenocarcinoma
6 22927 1 16990962 17780550 Loss Pancreatic ductal adenocarcinoma
7 23665 1 172632928 173462394 Gain Pancreatic ductal adenocarcinoma
8 23983 1 174098656 174792564 Gain Pancreatic ductal adenocarcinoma
9 24268 1 17780550 18767187 Loss Pancreatic ductal adenocarcinoma
10 25340 1 18767187 19870518 Loss Pancreatic ductal adenocarcinoma
11 25429 1 189012940 189640525 Gain Pancreatic ductal adenocarcinoma
12 25525 1 190940606 191897513 Gain Pancreatic ductal adenocarcinoma
13 25603 1 191897513 192833019 Gain Pancreatic ductal adenocarcinoma
14 25668 1 192833019 193928417 Gain Pancreatic ductal adenocarcinoma
15 25957 1 195125528 196179631 Gain Pancreatic ductal adenocarcinoma
16 26123 1 197274194 198251428 Gain Pancreatic ductal adenocarcinoma
17 26286 1 19870518 21264484 Loss Pancreatic ductal adenocarcinoma
18 27649 1 210637543 211466127 Gain Pancreatic ductal adenocarcinoma
19 29512 1 232834654 234059648 Gain Pancreatic ductal adenocarcinoma
20 29988 1 23881482 24596143 Loss Pancreatic ductal adenocarcinoma
21 30783 1 24596143 24901021 Loss Pancreatic ductal adenocarcinoma
22 31049 1 24901021 26202341 Loss Pancreatic ductal adenocarcinoma
23 31229 1 26202341 27453508 Loss Pancreatic ductal adenocarcinoma
24 31475 1 27702974 28279739 Loss Pancreatic ductal adenocarcinoma
25 31649 1 29154418 29949616 Loss Pancreatic ductal adenocarcinoma
26 31710 1 29949616 31202941 Loss Pancreatic ductal adenocarcinoma
27 31822 1 31202941 32179980 Loss Pancreatic ductal adenocarcinoma
28 32104 1 33581730 34569385 Loss Pancreatic ductal adenocarcinoma
29 32211 1 34569385 35804738 Loss Pancreatic ductal adenocarcinoma
30 32498 1 36953732 37599763 Loss Pancreatic ductal adenocarcinoma
31 32649 1 38143717 38830556 Loss Pancreatic ductal adenocarcinoma
32 32759 1 3913633 5229374 Loss Pancreatic ductal adenocarcinoma
33 33297 1 44268667 45000776 Loss Pancreatic ductal adenocarcinoma
34 33745 1 47532872 48556325 Loss Pancreatic ductal adenocarcinoma
35 34094 1 5229374 6509870 Loss Pancreatic ductal adenocarcinoma
36 34199 1 53371440 53750907 Loss Pancreatic ductal adenocarcinoma
37 34230 1 53750907 54788971 Loss Pancreatic ductal adenocarcinoma
38 36948 1 8379388 9142502 Loss Pancreatic ductal adenocarcinoma
39 37455 1 9142502 9661749 Loss Pancreatic ductal adenocarcinoma
40 38508 10 103075332 103271952 Gain Pancreatic ductal adenocarcinoma
41 41307 10 15917593 17007248 Gain Pancreatic ductal adenocarcinoma
42 41728 10 22854210 23744923 Gain Pancreatic ductal adenocarcinoma
43 44446 10 57203760 58367659 Gain Pancreatic ductal adenocarcinoma
44 44911 10 64846281 66342495 Gain Pancreatic ductal adenocarcinoma
45 45553 10 72143312 73316160 Loss Pancreatic ductal adenocarcinoma
46 45655 10 73316160 74391172 Gain Pancreatic ductal adenocarcinoma
47 45775 10 74391172 75333936 Gain Pancreatic ductal adenocarcinoma
48 45937 10 75333936 76299818 Gain Pancreatic ductal adenocarcinoma
49 46231 10 79273961 80171344 Loss Pancreatic ductal adenocarcinoma
50 46288 10 80171344 81279277 Loss Pancreatic ductal adenocarcinoma

Expression for Pancreatic Ductal Adenocarcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Pancreatic Ductal Adenocarcinoma patients vs. healthy controls: 35 (show top 50) (show all 375)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SYCN syncollin Pancreas - 8.04 0.000
2 GP2 glycoprotein 2 (zymogen granule membrane) Pancreas - 7.99 0.000
3 ALB albumin Pancreas - 7.95 0.000
4 SERPINI2 serpin peptidase inhibitor, clade I (pancpin), member 2 Pancreas - 7.95 0.000
5 CELA2B chymotrypsin-like elastase family, member 2B Pancreas - 7.74 0.000
6 PNLIPRP1 pancreatic lipase-related protein 1 Pancreas - 7.66 0.000
7 PDIA2 protein disulfide isomerase family A, member 2 Pancreas - 7.53 0.000
8 SPX spexin hormone Pancreas - 7.53 0.000
9 CTRL chymotrypsin-like Pancreas - 7.52 0.000
10 COL10A1 collagen, type X, alpha 1 Pancreas + 7.52 0.000
11 CELP carboxyl ester lipase pseudogene Pancreas - 7.50 0.000
12 COL5A1 collagen, type V, alpha 1 Pancreas + 7.46 0.000
13 SULF1 sulfatase 1 Pancreas + 7.38 0.000
14 CUZD1 CUB and zona pellucida-like domains 1 Pancreas - 7.29 0.000
15 POSTN periostin, osteoblast specific factor Pancreas + 7.24 0.000
16 COL1A1 collagen, type I, alpha 1 Pancreas + 7.17 0.000
17 AQP8 aquaporin 8 Pancreas - 7.14 0.000
18 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 Pancreas + 7.10 0.000
19 COL11A1 collagen, type XI, alpha 1 Pancreas + 7.00 0.000
20 CLPS colipase, pancreatic Pancreas - 6.99 0.000
21 INHBA inhibin, beta A Pancreas + 6.95 0.000
22 CPA2 carboxypeptidase A2 (pancreatic) Pancreas - 6.88 0.000
23 CTRC chymotrypsin C (caldecrin) Pancreas - 6.87 0.000
24 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) Pancreas + 6.86 0.000
25 PLA2G1B phospholipase A2, group IB (pancreas) Pancreas - 6.79 0.001
26 COL3A1 collagen, type III, alpha 1 Pancreas + 6.78 0.000
27 SFRP4 secreted frizzled-related protein 4 Pancreas + 6.76 0.000
28 CELA3A chymotrypsin-like elastase family, member 3A Pancreas - 6.76 0.001
29 GNMT glycine N-methyltransferase Pancreas - 6.74 0.000
30 COL1A2 collagen, type I, alpha 2 Pancreas + 6.72 0.000
31 REG1P regenerating islet-derived 1 pseudogene Pancreas - 6.72 0.000
32 S100P S100 calcium binding protein P Pancreas + 6.67 0.000
33 CELA3B chymotrypsin-like elastase family, member 3B Pancreas - 6.66 0.001
34 CEL carboxyl ester lipase Pancreas - 6.63 0.001
35 CTHRC1 collagen triple helix repeat containing 1 Pancreas + 6.60 0.000
36 CPA1 carboxypeptidase A1 (pancreatic) Pancreas - 6.56 0.001
37 VCAN versican Pancreas + 6.51 0.000
38 TMEM52 transmembrane protein 52 Pancreas - 6.40 0.000
39 REG1B regenerating islet-derived 1 beta Pancreas - 6.35 0.002
40 CTSE cathepsin E Pancreas + 6.30 0.000
41 GLS2 glutaminase 2 (liver, mitochondrial) Pancreas - 6.28 0.000
42 KLK1 kallikrein 1 Pancreas - 6.26 0.000
43 GJB2 gap junction protein, beta 2, 26kDa Pancreas + 6.24 0.000
44 REG3G regenerating islet-derived 3 gamma Pancreas - 6.17 0.000
45 PLAU plasminogen activator, urokinase Pancreas + 6.15 0.000
46 COL5A2 collagen, type V, alpha 2 Pancreas + 6.13 0.000
47 SLC39A5 solute carrier family 39 (zinc transporter), member 5 Pancreas - 6.09 0.000
48 ERP27 endoplasmic reticulum protein 27 Pancreas - 6.07 0.000
49 SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C Pancreas + 6.00 0.000
50 PNLIP pancreatic lipase Pancreas - 5.94 0.004
Search GEO for disease gene expression data for Pancreatic Ductal Adenocarcinoma.

Pathways for Pancreatic Ductal Adenocarcinoma

GO Terms for Pancreatic Ductal Adenocarcinoma

Biological processes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of activated T cell proliferation GO:0042104 9.16 MIR155 MIR21
2 positive regulation of cardiac muscle hypertrophy GO:0010613 8.96 MIR155 MIR21
3 negative regulation of regulatory T cell differentiation GO:0045590 8.62 MIR155 MIR21

Sources for Pancreatic Ductal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....